Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ZYPREXA
Olanzapine Immediate Release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Olanzapine (Fast-D) 425mg | EXPERIMENTAL | Single-dose injection |
| Olanzapine (To-be-marketed) 425mg | EXPERIMENTAL | Single-dose injection |
| Olanzapine (Slow-C) 425mg | EXPERIMENTAL | Single-dose injection |
| ZYPREXA 5mg | EXPERIMENTAL | Single-dose injection |
| Name | Type | Description |
|---|---|---|
| Olanzapine Extended Release | DRUG | Powder and vehicle for injectable suspension |
| Olanzapine Immediate Release | DRUG | IntraMuscular Injection |
Inclusion Criteria: * Body weight \>50 kg and body mass index (BMI) within the range 18.5 to 38.0 kg/m2, inclusive, at the time of screening * Agree to maintain current smoking or nonsmoking status at the time informed consent is obtained and throughout the trial until completion of the end of trea...
Olanzapine Immediate Release is being developed for the treatment of schizophrenia and schizoaffective disorder. It is an immediate-release formulation of olanzapine, an antipsychotic small molecule. Teva Pharmaceutical Industries Limited is the developer. The program is in Phase 1 clinical development.
Olanzapine Immediate Release targets dopamine receptors DRD2, DRD3, and DRD4, and serotonin receptors HTR2A and HTR2C. It acts as an antagonist at these receptors. This receptor binding profile is characteristic of atypical antipsychotic activity relevant to schizophrenia and schizoaffective disorder.
Teva Pharmaceutical Industries Limited is developing Olanzapine Immediate Release. Teva trades on the New York Stock Exchange under the ticker TEVA. The company is responsible for the clinical development of this immediate-release olanzapine formulation for schizophrenia and schizoaffective disorder.
Olanzapine Immediate Release is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. The program includes one completed Phase 1 trial with 106 participants. No active trials are currently listed for this asset.
Olanzapine Immediate Release has been studied in one completed Phase 1 trial, NCT06319170. The trial was an open-label study characterizing the pharmacokinetics of three subcutaneous olanzapine extended-release formulations in participants with schizophrenia or schizoaffective disorder. It enrolled 106 participants in the United States and was controlled and randomized.